Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 VLA15 Lyme disease vaccine trial
2023-509105-72-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, single-blind trial in Lyme borreliosis comparing VLA15 vaccine with Placebo (2 arms). Primary endpoints: Clinically and laboratory confirmed Lyme disease caused by B burgdorferi sensu lato, Local reactions and 5 more. Started Oct 2024; status: completed.
02
Drugs
Lyme Disease Vaccine Recombinant OspA
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on 2023-509105-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509105-72-00.